modelR06AE09
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Levocetirizine | |
| ATC code: | R06AE09 | route: | oral |
| compartments: | 1 | |
| dosage: | 5 | mg |
| volume of distribution: | 0.4 | L |
| clearance: | 0.63 | L/h/kg |
| other parameters in model implementation | ||
Levocetirizine is a selective, non-sedating antihistamine used primarily for the symptomatic relief of allergic rhinitis (including hay fever) and chronic idiopathic urticaria. It is the levo-enantiomer of cetirizine and is available as an approved medication in many countries for both adults and children.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult subjects following oral administration of a single 5 mg dose.
References
Simons, FE (2005). Population pharmacokinetics of levocetirizine in very young children: the pediatricians' perspective. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 16(2) 97–103. DOI:10.1111/j.1399-3038.2005.00240.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/15787865
Ino, H, et al., & Fukase, H (2014). Comparison of levocetirizine pharmacokinetics after single doses of levocetirizine oral solution and cetirizine dry syrup in healthy Japanese male subjects. Journal of drug assessment 3(1) 38–42. DOI:10.3109/21556660.2014.928302 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27536452
Hussein, Z, et al., & Stockis, A (2005). Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. British journal of clinical pharmacology 59(1) 28–37. DOI:10.1111/j.1365-2125.2005.02242.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/15606437
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)